CSI 2021: COMPASS Trial: How it has Changed Life?
Dr J Ezhilan, Chennai, 26 January 2022
remove_red_eye 2346 Views
#Multispeciality
Coronavirus Live Count Map India
remove_red_eye 2346 Views
COVID-19 Vaccine Updates
#Multispeciality
The COMPASS trial for the first time has shown that dual pathway inhibition with low-dose rivaroxaban and aspirin has a favorable benefit risk profile in patients with polyvascular disease like CAD, PAD and cerebrovascular disease.
Since benefit is seen more in <65-year population than >65-year population, Indian patients who are younger will benefit more from the dual pathway inhibition therapy.
To comment on this article ,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
Young adults less than 65 will get benefits of this combination